Evidence map›Paper›PMID 35571452›Full record

ArticleAnnals of translational medicine2022

Prognostic role of immune microenvironment in pleural metastases from breast and lung adenocarcinomas.

Georgia Karpathiou, Jonas Benli, Anne Laure Désage, Mathilde Jacob, Olivier Tiffet, Michel Peoc'h, Marios E Froudarakis

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. The Premetastatic Lymph Node Niche in Gynecologic Cancer.International journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Georgia KarpathiouDepartment of Pathology, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Jonas BenliDepartment of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Anne Laure DésageDepartment of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Mathilde JacobDepartment of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Olivier TiffetDepartment of Thoracic Surgery, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Michel Peoc'hDepartment of Pathology, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Marios E FroudarakisDepartment of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Institute Cancer De La Loire Lucien Neuwirth · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pleural metastatic disease is a common disease with dismal prognosis. The immune microenvironment of metastatic pleural tissue remains largely unknown. Thus, we aimed to investigate the presence of different immune cell populations, and to compare them with clinical characteristics. Methods: We included 70 patients with lung and breast adenocarcinoma (ADC) diagnosed with pleural metastasis during a 2-year period with the primary endpoint to investigate if the main immune cell populations are present in pleural metastases and if they have any prognostic role. Secondary endpoints were to detect any differences in their presence between lung and breast primaries and to search for any correlation with the macroscopic (thoracoscopic) findings. We used immunohistochemical techniques for the detection of CD4 Results: Primary endpoint: all these populations are present in the biopsies from lung and higher stromal and intratumoral CD4 counts, as well as higher stromal CD20 cells were positive prognostic factors for lung cancer metastases, while higher S100 intratumoral counts were positive prognostic factors in lung and marginally breast cancer metastases. Secondary endpoints: significant higher values for the stromal CD163 group (P=0.04) and for the intratumoral S100 group (P=0.006) were seen in lung compared to breast metastases. Interesting correlations were also noted between thoracoscopic findings (nodules, masses, pachypleuritis) and the different factors studied. Conclusions: Our data show that the immune microenvironment may be important in this advanced tumoral setting and that possible targets of the nowadays numerous treatment strategies implicating the immune system may merit further exploration in this poor prognosis disease.

Indexed as

adenocarcinoma (ADC)breast cancerlung cancermicroenvironmentPleural disease

Identifiers

PMID35571452
PMCPMC9096424
OpenAlexW4247034936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.